Search

Displaying results 3401 - 3410 of 9670 in total
  1. Drug

    Inosine pranobex

    go.drugbank.com/drugs/DB13156
    Approved

    Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

  2. Drug

    Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

    go.drugbank.com/drugs/DB16757
    Approved

    [L40694] While the concept of plant-based VLPs as vaccines is not new,[A245824] it is a novel approach to COVID-19 vaccination, with previously approved COVID-19 vaccines mostly comprising viral vector … [A245819] Plant-based VLPs offer a number of advantages as compared to other vaccine platforms, including speed and ease of manufacturing and increased immunogenicity.

  3. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Once bound to fibrin, it will cause fibrin accretion(clot formation) to a degree 18 folds greater than thrombin. … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen.

  4. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals.

  5. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. … Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  6. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione has been investigated for the treatment of Blood Coagulation Disorders. … Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

  7. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)

  8. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394] … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.

  9. Drug

    Creatine

    go.drugbank.com/drugs/DB00148
    ApprovedInvestigationalNutraceutical

    In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.

  10. Drug

    Formic acid

    go.drugbank.com/drugs/DB01942
    ApprovedInvestigational

    It is commonly used as a preservative and antibacterial agent in livestock feed. … It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings.